H.C. Wainwright lowered the firm’s price target on Anavex (AVXL) to $20 from $42 and keeps a Buy rating on the shares after blarcamesine received a negative trend opinion from European regulators. The firm cites the reduced probability of approval for blarcamesine in Europe for treatment of Alzheimer’s disease for the target cut.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL: